{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer's", "Anxiety", "Biosynthesis", "Depression", "Mangiferin", "Neuroaging", "Neurodegenerative", "Neuroinflammation", "Neuropsychiatric", "Parkinson's", "Pharmacokinetics", "Xanthone"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "33346032", "DateCompleted": {"Year": "2021", "Month": "11", "Day": "04"}, "DateRevised": {"Year": "2021", "Month": "11", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "12", "Day": "17"}], "Language": ["eng"], "ELocationID": ["10.1016/j.neuint.2020.104939", "S0197-0186(20)30330-2"], "Journal": {"ISSN": "1872-9754", "JournalIssue": {"Volume": "143", "PubDate": {"Year": "2021", "Month": "Feb"}}, "Title": "Neurochemistry international", "ISOAbbreviation": "Neurochem Int"}, "ArticleTitle": "Therapeutic potential of mangiferin in the treatment of various neuropsychiatric and neurodegenerative disorders.", "Pagination": {"StartPage": "104939", "MedlinePgn": "104939"}, "Abstract": {"AbstractText": ["Xanthones are important chemical class of bioactive products that confers therapeutic benefits. Of several xanthones, mangiferin is known to be distributed widely across several fruits, vegetables and medicinal plants. Mangiferin has been shown to exert neuroprotective effects in both in-vitro and in-vivo models. Mangiferin attenuates cerebral infarction, cerebral edema, lipid peroxidation (MDA), neuronal damage, etc. Mangiferin further potentiate levels of endogenous antioxidants to confer protection against the oxidative stress inside the neurons. Mangiferin is involved in the regulation of various signaling pathways that influences the production and levels of proinflammatory cytokines in brain. Mangiferin cosunteracted the neurotoxic effect of amyloid-beta, MPTP, rotenone, 6-OHDA etc and confer protection to neurons. These evidence suggested that the mangiferin may be a potential therapeutic strategy for the treatment of various neurological disorders. The present review demonstrated the pharmacodynamics-pharmacokinetics of mangiferin and neurotherapeutic potential in several neurological disorders with underlying mechanisms."], "CopyrightInformation": "Copyright \u00a9 2020 Elsevier Ltd. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, DIT University, Dehradun, India. Electronic address: vaibhav.walia00@gmail.com."}], "LastName": "Walia", "ForeName": "Vaibhav", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, DIT University, Dehradun, India. Electronic address: sushil.chaudhary@dituniversity.edu.in."}], "LastName": "Chaudhary", "ForeName": "Sushil Kumar", "Initials": "SK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, DIT University, Dehradun, India. Electronic address: neeraj.sethiya@dituniversity.edu.in."}], "LastName": "Kumar Sethiya", "ForeName": "Neeraj", "Initials": "N"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Neurochem Int", "NlmUniqueID": "8006959", "ISSNLinking": "0197-0186"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Neuroprotective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Xanthones"}, {"RegistryNumber": "1M84LD0UMD", "NameOfSubstance": "mangiferin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Brain"}, {"QualifierName": ["psychology"], "DescriptorName": "Cognitive Aging"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "metabolism", "psychology"], "DescriptorName": "Mental Disorders"}, {"QualifierName": ["drug therapy", "metabolism", "psychology"], "DescriptorName": "Neurodegenerative Diseases"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Neuroprotective Agents"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Xanthones"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2020", "Month": "6", "Day": "29"}, {"Year": "2020", "Month": "11", "Day": "2"}, {"Year": "2020", "Month": "12", "Day": "12"}, {"Year": "2020", "Month": "12", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "12", "Day": "21", "Hour": "8", "Minute": "44"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33346032", "10.1016/j.neuint.2020.104939", "S0197-0186(20)30330-2"]}}]}